Dynamic Profiling of the Immune Tumor Microenvironment in Locally Advanced Gastric Cancer Treated with Perioperative Chemotherapy

Oncology. 2023;101(7):435-445. doi: 10.1159/000530853. Epub 2023 Jun 12.

Abstract

Introduction: In locally advanced gastric cancer (GC), FLOT represents the standard perioperative regimen and combination with immunotherapy is under investigation. However, the role of immune tumor microenvironment (TME) is poorly recognized in this setting. We aimed to study TME characteristics and dynamics during FLOT.

Methods: Paired biopsy (PRE) and surgical (POST) samples of 25 patients treated with FLOT were prospectively analyzed. After collection of clinic-pathological data, NanoString analyses were performed. The primary objective of the study was to assess the changes induced by chemotherapy in POST compared to PRE samples.

Results: The unsupervised hierarchical method analysis clearly distinguished PRE and POST samples, even though some cases showed high immune gene expression at baseline. When POST samples were compared with PRE, a differential expression in hyper-expressed gene sets related to cytotoxicity, T-cell functions, complement system, tumor necrosis factor superfamily, cell cycle, and regulation was recognized. Downstaging of the primary tumor (T-regression, measured by pathologic compared to clinical T stage) was the covariate most frequently associated with these changes. Using the immune cell profiling, cases with T-regression reported a significant increase of T, CD8+ T and B cells and a decrease in mast cells, while nonresponders demonstrated an increase of T, B, cytotoxic, and mast cells.

Conclusion: Our analysis shows that FLOT significantly influences immune TME of GC. While relevant modifications preferentially occur in tumors showing primary tumor regression, response to treatment seems to be associated with a specific immune profile.

Keywords: 5-Fluorouracil/leucovorin, oxaliplatin, docetaxel; Gastric cancer; Immune profiling; NanoString; Tumor microenvironment.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Docetaxel
  • Fluorouracil
  • Humans
  • Leucovorin
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / pathology
  • Stomach Neoplasms* / surgery
  • Tumor Microenvironment

Substances

  • Docetaxel
  • Fluorouracil
  • Leucovorin